Organ‐Specific Efficacy of Postischemic Empagliflozin in Acute Stroke and Myocardial Infarction Using Preclinical Models
Journal of the American Heart Association · 02.06.2026 · 15 (11)
DOI: 10.1161/jaha.125.047087 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Heart Association, erschienen am 02.06.2026. Verfasst von Jiajun Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Aerospace and Mechanical Engineering University of Southern California Los Angeles CA USA. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Glucosides, Myocardial Infarction, Infarction, Middle Cerebral Artery. Die Arbeit nennt 79 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Schlaganfall
Abstract (Originalsprache)
Background
Empagliflozin, a sodium–glucose cotransporter 2 inhibitor, has demonstrated cardioprotective and neuroprotective effects in preclinical myocardial infarction (MI) and ischemic stroke settings by reducing acute myocardial and cerebral infarction sizes. However, the optimal administration for acute protection remains unclear. Particularly, empagliflozin effects when administered after ischemia onset but before reperfusion have not been systematically evaluated for acute MI and stroke models.
Methods
Sprague–Dawley rats underwent either middle cerebral artery occlusion/reperfusion to induce acute ischemic stroke (n=25), or left coronary artery occlusion/reperfusion to induce acute MI (n=29). Empagliflozin (20 mg/kg) or saline was administered 10 minutes after ischemia onset. Outcomes included brain/heart injury sizes and cardiac hemodynamics were quantified after 3 hours of reperfusion.
Results
In the stroke model, postocclusion empagliflozin administration significantly reduced cerebral total infarct volume compared with controls (80.83±16.59 versus 164.10±26.23 mm 3 , P =0.014), corresponding to ≈50% reduction in the infarct volume percentage, while edema was unchanged. In the MI model, empagliflozin did not reduce myocardial infarct size, ischemic risk area, or no‐reflow zone when given after occlusion/before reperfusion.
Conclusions
Our findings highlight that empagliflozin, when administered after ischemia onset but before reperfusion, provides robust neuroprotection in acute ischemic stroke but fails to limit myocardial injury in acute MI. The divergent outcomes may reflect organ‐specific pathophysiology; for example, cerebral collaterals preserve residual perfusion and drug delivery, whereas limited cardiac collateralization leads to rapid necrosis and poor drug access. Clinically, these findings suggest that early postocclusion empagliflozin therapy may be beneficial in ischemic stroke, whereas comparable early administration appears insufficient in MI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Aerospace and Mechanical Engineering University of Southern California Los Angeles CA USA.
- Cardiovascular Research Institute Huntington Medical Research Institutes Pasadena CA USA.
- Division of Cardiovascular Medicine, Keck School of Medicine University of Southern California Los Angeles CA USA.
- Department of Medical Engineering California Institute of Technology Pasadena CA USA.
ORCID-Profile: Jiajun Li, Wangde Dai, Rashid Alavi, Xianghong Arakaki, Niema M Pahlevan, Robert A Kloner
Zitieren
APA
Li, J., Dai, W., Alavi, R., Carreno, J., Arakaki, X., Pahlevan, N. M., & Kloner, R. A. (2026). Organ‐Specific Efficacy of Postischemic Empagliflozin in Acute Stroke and Myocardial Infarction Using Preclinical Models. Journal of the American Heart Association, 15(11). https://doi.org/10.1161/jaha.125.047087
Vancouver
Li J, Dai W, Alavi R, Carreno J, Arakaki X, Pahlevan NM, et al. Organ‐Specific Efficacy of Postischemic Empagliflozin in Acute Stroke and Myocardial Infarction Using Preclinical Models. Journal of the American Heart Association. 2026;15(11). doi:10.1161/jaha.125.047087
BibTeX
@article{Li2026,
author = {Li, Jiajun and Dai, Wangde and Alavi, Rashid and Carreno, Juan and Arakaki, Xianghong and Pahlevan, Niema M and Kloner, Robert A},
title = {Organ‐Specific Efficacy of Postischemic Empagliflozin in Acute Stroke and Myocardial Infarction Using Preclinical Models},
journal = {Journal of the American Heart Association},
year = {2026},
volume = {15},
number = {11},
doi = {10.1161/jaha.125.047087}
}
EUVIMED